December 15, 9:15 - 10:15

Title of Symposium

• Role of Tumor Treatment Fields (TTFields) in the Management of Recurrent Ovarian Cancer

Moderator

• Waleed Shalaby, MD PhD, Senior Medical Director, NOVOCURE

Objectives for Symposium

• What are TTFields and the mechanism of action (MOA)?
• Review clinical data in recurrent ovarian cancer (ROC)
• Present ongoing Phase 3 registration trial in ROC (ENGOT-ov50/INNOVATE-3 study )
• Engage a panel discussion on the future role of TTFields in ovarian cancer

Agenda and Speakers (Tentative)

• Who is NOVOCURE?

Ely Benaim, MD (~3-5 min), Chief Medical Officer, NOVOCURE

• What are TTFields?

Moshe Giladi, PhD (~10 min), Dir. Preclinical Research, NOVOCURE

• INNOVATE Pilot Study in ROC

Prof. Ignace Vergote, MD PhD (~10 min), Catholic University of Leuven, Belgium

• ENGOT-ov50/INNOVATE-3 study Trial in ROC

Prof. David O’Malley MD (~10 min), Ohio State University, Columbus Ohio, USA

• Panel Discussion – Current and Future Opportunities (~30 min)

Prof. Ignace Vergote, MD PhD (moderator)

Invited Panel Member

• Prof. David O’Malley MD
• Prof. Nicoletta Colombo MD PhD, European Institute of Oncology, Milan, Italy
• Vanda Salutari, MD, Policlinico Agostino Gemelli of Rome, Italy
• Prof. Bradley Monk, MD, FACOG, FACS, University of Arizona College of Medicine, Phoenix AZ, USA
• Moshe Giladi PhD
• Uri Weinberg, MD PhD, VP Clinical Development, NOVOCURE